[go: up one dir, main page]

WO1996017869A3 - Interleukin-6 (il-6) antagonists - Google Patents

Interleukin-6 (il-6) antagonists Download PDF

Info

Publication number
WO1996017869A3
WO1996017869A3 PCT/IT1995/000208 IT9500208W WO9617869A3 WO 1996017869 A3 WO1996017869 A3 WO 1996017869A3 IT 9500208 W IT9500208 W IT 9500208W WO 9617869 A3 WO9617869 A3 WO 9617869A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
shil
asn
abnormal
interleukin
Prior art date
Application number
PCT/IT1995/000208
Other languages
French (fr)
Other versions
WO1996017869A2 (en
Inventor
Gennaro Ciliberto
Carlo Toniatti
Original Assignee
Angeletti P Ist Richerche Bio
Gennaro Ciliberto
Carlo Toniatti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio, Gennaro Ciliberto, Carlo Toniatti filed Critical Angeletti P Ist Richerche Bio
Priority to AU41866/96A priority Critical patent/AU4186696A/en
Priority to EP95940401A priority patent/EP0742794A1/en
Priority to JP8517466A priority patent/JPH09503232A/en
Publication of WO1996017869A2 publication Critical patent/WO1996017869A2/en
Publication of WO1996017869A3 publication Critical patent/WO1996017869A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

These are antagonists of interleukin-6, characterised in that they consist of soluble forms of the receptor α of human IL-6 (shIL-6Rα) containing one or more mutation in the gp130 binding interface. In a preferred embodiment, the mutations are present in a position chosen from the group comprising Ala 228, Asn 230, His 280 and Asp 281. These antagonists can be used as agents capable of preventing and treating diseases caused by abnormal IL-6 activity. The figure shows the antagonist activity of the mutant Ala228Asp/Asn 230Asp/His280Ser/Asp281Val in comparison with the agonist properties of wild type shIL-6Rα. This antagonist can be used for preparation of drugs for the prevention, control and treatment of diseases caused by abnormal IL-6 bioactivity.
PCT/IT1995/000208 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists WO1996017869A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU41866/96A AU4186696A (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
EP95940401A EP0742794A1 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
JP8517466A JPH09503232A (en) 1994-12-06 1995-12-05 An IL-6 antagonist that is a soluble form of interleukin-6 (IL-6) receptor alpha mutated at the GP130 binding interface

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM94A000794 1994-12-06
ITRM940794A IT1274350B (en) 1994-12-06 1994-12-06 INTERLEUCHINA-6 (IL-6) ANTAGONISTS, WHICH CONSIST OF SOLUBLE FORMS OF THE ALFA RECEPTOR OF IL-6, CHANGED IN THE INTERFACE THAT LINKS TO GP 130

Publications (2)

Publication Number Publication Date
WO1996017869A2 WO1996017869A2 (en) 1996-06-13
WO1996017869A3 true WO1996017869A3 (en) 1996-08-29

Family

ID=11402851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1995/000208 WO1996017869A2 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists

Country Status (7)

Country Link
EP (1) EP0742794A1 (en)
JP (1) JPH09503232A (en)
CN (1) CN1139933A (en)
AU (1) AU4186696A (en)
CA (1) CA2177837A1 (en)
IT (1) IT1274350B (en)
WO (1) WO1996017869A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
CA2230949C (en) * 1995-09-28 2009-11-17 Judith Chebath Synthetic peptides that inhibit il-6 activity
US6217858B1 (en) 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
EP0983767B1 (en) 1997-03-21 2008-09-10 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for the treatment of multiple sclerosis containing antagonist anti-IL-6-receptor antibodies
US7227837B1 (en) 1998-04-30 2007-06-05 At&T Labs, Inc. Fault tolerant virtual tandem switch
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US8440196B1 (en) 1998-08-24 2013-05-14 Chugai Seiyaku Kabushiki Kaisha Treatment for pancreatitis using IL-6 receptor antagonist antibodies
JP4799516B2 (en) * 1998-08-24 2011-10-26 中外製薬株式会社 A prophylactic or therapeutic agent for pancreatitis comprising an IL-6 antagonist as an active ingredient
ATE372126T1 (en) * 1998-11-05 2007-09-15 Omeros Corp FLUSH SOLUTION AND METHOD FOR PAIN RELIEF AND ANTI-INFLAMMATORY
WO2001016166A2 (en) 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AUPR769501A0 (en) * 2001-09-14 2001-10-11 Biomolecular Research Institute Limited Cytokine receptor 1
WO2004073741A1 (en) 2003-02-24 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Remedy for spinal injury containing interleukin-6 antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1690550B1 (en) 2003-10-17 2012-08-08 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for mesothelioma
AR048210A1 (en) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd A PREVENTIVE AGENT FOR VASCULITIS.
BRPI0617378B8 (en) 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd USE OF AN IL-6 INHIBITOR TO PRODUCE A PHARMACEUTICAL COMPOSITION TO SUPPRESS DAMAGE TO AN ISLE TRANSPLANTATION AFTER ISLE TRANSPLANTATION; AND IMPROVE THE FEASIBILITY OF AN ISLAND IN AN ISLAND TRANSPLANTATION
BRPI0617664B8 (en) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd use of an antibody recognizing IL-6 for the production of a pharmaceutical composition to treat myocardial infarction or suppress left ventricular remodeling after myocardial infarction
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
WO2007061029A1 (en) 2005-11-25 2007-05-31 Keio University Therapeutic agent for prostate cancer
JP5033643B2 (en) 2006-01-27 2012-09-26 学校法人慶應義塾 Therapeutic agent for diseases associated with choroidal neovascularization
JP5754875B2 (en) 2006-04-07 2015-07-29 国立大学法人大阪大学 Muscle regeneration promoter
AU2008208321B2 (en) 2007-01-23 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Chronic rejection inhibitor
CN104906581A (en) 2008-06-05 2015-09-16 国立研究开发法人国立癌症研究中心 Neuroinvasion inhibitor
WO2011149046A1 (en) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター Therapeutic agent for pancreatic cancer
PL2578231T3 (en) 2010-05-28 2023-01-16 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
JP6442404B2 (en) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター Method for predicting treatment prognosis in patients with relapsing-remitting multiple sclerosis (RRMS), and method for determining new treatment indication
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
ES2967627T3 (en) 2015-02-27 2024-05-03 Chugai Pharmaceutical Co Ltd Composition to treat diseases related to IL-6
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
TWI822728B (en) 2018-01-31 2023-11-21 加藤元一 Asthma therapeutic agents containing IL-6 inhibitors
CA3103975A1 (en) * 2018-06-21 2019-12-26 Shattuck Labs, Inc. Heterodimeric proteins and uses thereof
BR112021020525A2 (en) 2019-04-17 2021-12-14 Chugai Pharmaceutical Co Ltd Therapeutic agent for urological cancer that is characterized by being administered with an IL-6 inhibitor and CCR2 inhibitor in combination
CN110133241B (en) * 2019-05-21 2022-05-27 中国食品药品检定研究院 Novel method for measuring biological activity of recombinant human soluble gp130-Fc fusion protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591892A (en) * 1991-10-02 1993-04-16 Chuzo Kishimoto Il-6 receptor derivative

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591892A (en) * 1991-10-02 1993-04-16 Chuzo Kishimoto Il-6 receptor derivative

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE STRAND TPSD *
DATABASE WPI Week 9320, Derwent World Patents Index; AN 93-161739, XP002003861 *
LIAUTARD ET AL.: "Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies", EUR. CYTOKINE NETWORK, vol. 5, no. 3, May 1994 (1994-05-01) - June 1994 (1994-06-01), pages 293 - 300, XP000571448 *
SALVATI ET AL.: "Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor alpha mutated in the predicted gp130-binding interface", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 20, 19 May 1995 (1995-05-19), pages 12242 - 12249, XP000566420 *
TAGA ET AL.: "Interleukin-6 receptor and a unique mechanism of its signal transduction", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, vol. 54, 1989, pages 713 - 722, XP002003860 *
YAWATA ET AL.: "Structure-function analysis of human IL-6 receptor : dissociation of amino acid residues required for IL-6-binding and IL-6 signal transduction through gp130", EMBO J., vol. 12, no. 4, 1993, pages 1705 - 1712, XP002003859 *

Also Published As

Publication number Publication date
EP0742794A1 (en) 1996-11-20
CA2177837A1 (en) 1996-06-07
CN1139933A (en) 1997-01-08
AU4186696A (en) 1996-06-26
IT1274350B (en) 1997-07-17
ITRM940794A1 (en) 1996-06-06
WO1996017869A2 (en) 1996-06-13
ITRM940794A0 (en) 1994-12-06
JPH09503232A (en) 1997-03-31

Similar Documents

Publication Publication Date Title
WO1996017869A3 (en) Interleukin-6 (il-6) antagonists
Maurset et al. Comparison of ketamine and pethidine in experimental and postoperative pain
Chandra et al. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial.
CA2305799A1 (en) Composition for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
NZ305166A (en) 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
DE69834268D1 (en) PERCENTAGE TO BE DISCONTINUED TO A MEDICAL COMBINATION OF AN OPIOID AGONIST AND NALTREXON
SI0751129T1 (en) Substituted dihydrodibenzo(b,f)azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
Seibel et al. Cyclosporine‐induced gingival overgrowth in beagle dogs
EP0715855A3 (en) NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
HUP0101369A3 (en) Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
ATE547119T1 (en) PREVENTIVE OR THERAPEUTIC AGENT CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENTS FOR SENSITIZED T CELL-MEDIATED DISEASES
WO1998008546A3 (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
AU2928292A (en) Human il-4 mutant proteins
CA2176298A1 (en) A single high dose fluoroquinolone treatment
CA2132544A1 (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
WO2000002551A3 (en) Methods and compounds for treating depression
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
WO2023009615A3 (en) Methods and compositions for treating or preventing neurological injury or neurological disorders
WO2000025766A3 (en) Use of nk antagonist for treating gastric asthma
Risner et al. Intravenous self-administration of fencamfamine and cocaine by beagle dogs under fixed-ratio and progressive-ratio schedules of reinforcement
WO1998003178A3 (en) Pharmaceutical compositions containing p2y purinergic receptor antagonists
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95191457.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1995940401

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2177837

Country of ref document: CA

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1996 687490

Country of ref document: US

Date of ref document: 19961016

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995940401

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995940401

Country of ref document: EP